BR100 Increased By (0.75%)
BR30 Increased By (1.08%)
KSE100 Increased By (0.82%)
KSE30 Increased By (0.89%)
AGHA 6.44 Increased By ▲ 0.06 (0.94%)
BECO 4.33 Decreased By ▼ -0.02 (-0.46%)
BML 62.90 Increased By ▲ 0.35 (0.56%)
BOP 31.42 Increased By ▲ 0.03 (0.1%)
CNERGY 11.90 Increased By ▲ 0.17 (1.45%)
CSIL 5.90 Decreased By ▼ -0.01 (-0.17%)
FCCL 62.29 Increased By ▲ 0.58 (0.94%)
FFL 14.87 Increased By ▲ 0.08 (0.54%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.90 No Change ▼ 0.00 (0%)
LOTCHEM 24.78 Increased By ▲ 0.09 (0.36%)
MLCF 106.03 Increased By ▲ 2.10 (2.02%)
NBP 174.59 Increased By ▲ 1.27 (0.73%)
NCPL 52.30 Increased By ▲ 0.47 (0.91%)
NPL 55.00 Increased By ▲ 0.97 (1.8%)
OGDC 319.93 Increased By ▲ 4.06 (1.29%)
PACE 9.33 Increased By ▲ 0.07 (0.76%)
PAEL 35.87 Increased By ▲ 0.29 (0.82%)
PIBTL 13.90 Increased By ▲ 0.24 (1.76%)
PPL 228.51 Increased By ▲ 2.44 (1.08%)
PRL 81.91 Increased By ▲ 1.63 (2.03%)
PTC 47.19 Increased By ▲ 0.55 (1.18%)
SSGC 24.01 Increased By ▲ 0.19 (0.8%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.53 Decreased By ▼ -0.02 (-0.26%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.15 Increased By ▲ 0.16 (1.23%)
TREET 26.11 Increased By ▲ 0.13 (0.5%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)

WHO approves China’s Sinopharm vaccine for emergency use

  • WHO gave emergency use listing to Beijing's Sinopharm Covid-19 vaccine, making it the sixth overall, and the first Chinese vaccine to receive WHO validation for safety, efficacy, and quality.
Published Updated

The World Health Organization (WHO) on Friday approved the Sinpoharm vaccine for emergency use against the Covid-19. With this development, Sinopharm became China’s first coronavirus vaccine to get the WHO’s nod for international use.

Addressing a press conference in this regard, the WHO’s director-general, Tedros Adhanom Ghebreyesus said:

“This afternoon, WHO gave emergency use listing to Beijing's Sinopharm Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy, and quality.”

The other five emergency use vaccines to get WHO listings are made by Pfizer-BioNTech, Moderna, Johnson, and Johnson, and the AstraZeneca being produced at separate sites in India and in South Korea.

The approval means that Sinopharm will be included in Covax, the UN health agency’s global initiative that is designed to promote equitable vaccine distribution around the world.

According to an AFP, the Sinopharm vaccine being used in 42 territories around the world, is the fourth behind AstraZeneca (166), Pfizer-BioNTech (94), and Moderna (46).

Besides China, it is being used in Algeria, Cameroon, Egypt, Hungary, Iraq, Iran, Pakistan, Peru, the United Arab Emirates, Serbia, and Seychelles, among others.

It is a developing story, will be updated accordingly.

Comments

Comments are closed for this article.